Palladia Tablets For Cats

It works by cutting off blood supply to tumors and killing tumor cells in the dog s body.

Palladia tablets for cats.

However uncommon side effects such as hepatopathy azotaemia and lethargy may occur. Sold per tablet in 10 15 50 mg strengths. It treats mast tumor cells and helps shrink tumors. Palladia is specially formulated to treat cancer in dogs.

For oral use in dogs only. Palladia is an anti cancer drug that requires a prescription from your veterinarian. Free shipping and the best customer service. Palladia a tyrosine kinase inhibitor is a drug used to treat mast cell tumors a common form of cancer that affects dogs.

Palladia tablets 3 25 mg kg 1 48 mg lb administer an initial dosage of 3 25 mg kg 1 48 mg lb body weight orally every other day. Palladia tablets can be administered with or without food. Palladia is sold per tablet. In cats approximately 20 to 70 experience a side effect from palladia that is usually mild and temporary gastrointestinal signs predominately anorexia or bone marrow suppression neutropenia and thrombocytopaenia.

The active ingredient in palladia is toceranib phosphate. The dose given should be based on veterinary assessments conducted weekly for the first six weeks and thereafter every six weeks. The initial recommended dose of palladia for dogs is 3 25 mg kg bodyweight administered every second day see dosing table for details. This medication is sold per tablet and is available in 10 15 and 50 mg strengths.

Palladia tablets were administered orally to 20 male and 20 female adult dogs approximately 2 years of age at doses of 0 mg kg placebo 12 dogs 2 mg kg 0 5x 8 dogs 4 mg kg 1x 12 dogs or 6 mg kg 1 5x 8 dogs once every other day for 13 consecutive weeks without dose interruption. Palladia works by killing tumor cells and by cutting off the blood supply to the tumor. Palladia is a veterinarian prescribed medication used to treat cancer in dogs. Palladia a multi kinase inhibitor targeting several receptor tyrosine kinases rtk is the phosphate salt of toceranib.

The safe use of palladia hasn t been evaluated in dogs less than 24 months of age or weighing less than 11 lbs. During the blinded phase the objective response rate orr in dogs with lymph node involvement was 29 4 10 34 for palladia treated dogs compared to 4 1 25 for placebo treated dogs. Dose reductions of 0 5 mg kg to a minimum dose of 2 2 mg kg 1 0 mg lb every other day and dose interruptions cessation of palladia for up to two weeks may be utilized if needed to manage adverse reactions.